{"title":"Cancer immunology for the non-immunologist","authors":"J. Weber","doi":"10.1158/AACR.EDB-15-7955","DOIUrl":"https://doi.org/10.1158/AACR.EDB-15-7955","url":null,"abstract":"The immune system, which is capable of exquisite specificity while recognizing foreign and infectious antigens, with long-lasting memory that approximates the human lifespan, is profoundly suppressed in cancer-bearing patients. The development of vaccines against common infectious diseases is one of the great success stories of the last 150 years of medicine, yet to date no effective cancer vaccine has been developed, no doubt due to the complexity of immune evasion and suppression found in cancer. Many attempts have been made over the last century to alter immunity to cancer and, thereby, achieve tumor regression, but until the last 15 years, success has been infrequent, and confined to a small minority of patients with selected tumors like melanoma and kidney cancer treated with toxic cytokines like interleukin-2 and alpha interferon.Great interest in cancer immunology has been promoted recently by twomajor therapeutic advances: the development of checkpoint protein inhibition and adoptive cell therapy. These modalities are active in diverse histologies, with non-small cell lung cancer, head and neck cancer, ovarian cancer, cervical cancer, acute and chronic lymphocytic leukemia, and refractoryHodgkin's disease now counted among the tumors that can be treated effectively with immunotherapy.","PeriodicalId":404310,"journal":{"name":"Aacr Education Book","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124501810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cell line authentication to improve preclinical cancer research: Policies and training","authors":"L. Freedman, V. Siegel","doi":"10.1158/AACR.EDB-15-9039","DOIUrl":"https://doi.org/10.1158/AACR.EDB-15-9039","url":null,"abstract":"Irreproducible research is a pervasive, expensive, and well-recognized problem that con-tributes to both delays and costs of drug discovery and development (1, 2). One common and preventable contributor to irreproducible cancer research is the widespread use of misidenti fi ed (e.g., cellular cross-contamination), mislabeled, or interspecies-contaminated cell lines (3). Immortalized cancer cell lines have been used for decades as preclinical models for drug target discovery and in multiple areas of biomedical research (4). At the same time, the problem of altered genotypic and phenotypic function (i.e., \"drift\") as a result of over-passaging of cell lines also persists (5). The Global Biological Standards Institute (GBSI), a Washington, D.C.-based nonpro fi t, is leading a multipartner effort to build awareness among cancer researchers regarding the importance of cell authentication and to actively change laboratory practices and policies to produce more credible, reproducible, and translatable preclinical data and studies. As a result of targeted training, effective policies, and use of standards and best practices for authentication and cell culturing, (1) knowledge of why and how to perform cell authentication will improve, (2) research reproducibility problems involving cell lines will decrease, (3) millions of dollars in wasted research expenditures will be saved, and (4) translation time from bench to clinic to bedside will be decreased. A companion paper, Cell line authentication to improve preclinical cancer research: Methods in cell line authentication, quality control, and annotation, is also available.","PeriodicalId":404310,"journal":{"name":"Aacr Education Book","volume":"158 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123665645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Collaborating with industry to find chemical hits versus difficult targets","authors":"A. Jordan","doi":"10.1158/AACR.EDB-15-8389","DOIUrl":"https://doi.org/10.1158/AACR.EDB-15-8389","url":null,"abstract":"The contraction in early stage research within Pharma has seen a renaissance in drug discovery within the academic setting. However, certain challenges for these smaller units remain. Alongside the flow of quality, novel targets for exploitation, the delivery of quality hit matter against these targets can be challenging.Whilst oncogenic kinases are considered to be druggable and hit matter can often be found from relatively modest compound collections, more complex and challenging targets, such as certain epigenetic modifiers or protein-protein interactions, require larger compound collections to deliver quality hit matter. Furthermore, determining how druggable (or otherwise) a novel target may be, and thus the requirements in terms of the size of the collection to be screened, forms an important but often overlooked aspect of target evaluation. Through novel collaborative approaches, we have sought to address these issues in an effort to deliver credible, tractable, and robust hit matter against challenging and putatively \"undruggable\" targets in epigenetics and DNA repair (1).","PeriodicalId":404310,"journal":{"name":"Aacr Education Book","volume":"64 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130495790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Natural killer cells: Basic biology and immunotherapy potential","authors":"T. Fehniger","doi":"10.1158/AACR.EDB-15-8030","DOIUrl":"https://doi.org/10.1158/AACR.EDB-15-8030","url":null,"abstract":"Natural killer (NK) cells are innate lymphoid cells first discovered in the 1970s based upon their ability to kill immortalized cell lines without prior exposure, thereby distinguishing them fromT cells (1). Over the past four decades, key aspects of NK cell biology have been elucidated illuminating the complexity of their responses and function.We now understand that NK cells are critical for host defense against infection, andmediate antitumor immune responses (2). NK cells develop from progenitors in the bone marrow and complete their maturation in secondary lymphoid and peripheral tissues (3). Each mature NK cell integrates signals from a repertoire of inhibitory and activating receptors in order to determine the response to a target cell (4, 5). Due to the number and polymorphic nature of these germline encoded receptors, each individual potentially has thousands of NK cell subsets with differing reactivity profiles (6). NK cell tolerance to self is primarily based on inhibitory receptor recognition of self-MHC class I or class I-like molecules, whereby functional competence is linked to the expression of at least one inhibitory receptor that recognizes self, a process termed licensing or education (7). Activating receptors recognize abnormal or induced ligands in cells following viral infection or malignant transformation. NK cell responses are also coupled to adaptive immunity via activating Fc receptors (FcgRIIIa/CD16) that provide a strong trigger for antibody-opsonized target cells. Importantly, NK cells aremodulated by signals from constitutively expressed cytokine receptors (e.g., IL-2, IL-12, IL-15, IL-18, IL-21), which can result in NK cell activation, priming, and/or proliferation (8). Collectively, NK cell surface receptor signals trigger the primary function of NK cells, including direct cytotoxicity of target cells (9) and secretion of immunoregulatory cytokines (e.g. IFN-g) and chemokines (1, 8). NK cells do not act in isolation, but interact with many other immune cells resulting in cross talk that influences ongoing inflammatory or adaptive immune responses (10). Thus, our view of NK cells has transformed from a simple killer cell to an integrative innate lymphoid cell that bridges innate and adaptive immunity.","PeriodicalId":404310,"journal":{"name":"Aacr Education Book","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122076634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"ALK biology in health and disease","authors":"R. Palmer","doi":"10.1158/AACR.EDB-15-8746","DOIUrl":"https://doi.org/10.1158/AACR.EDB-15-8746","url":null,"abstract":"Anaplastic lymphoma kinase (ALK) was initially discovered as a 2;5 chromosomal translocation in Anaplastic Large-Cell Non-Hodgkin's lymphoma (ALCL), that produces the NPM-ALK fusion oncogene (1). The ALK receptor tyrosine kinase (RTK) is now a signi fi cant player in clinical oncology and has been implicated in many cancer types of cancer, arguably most well known in the form of the EML4-ALK oncogene in non-small cell lung cancer (NSCLC). The activation of ALK in tumors such as lung adenocarcinoma, has led to the FDA approval of ALK tyrosine kinase inhibitors (TKIs) such as crizotinib, ceritinib, and alectinib for use in a variety of ALK positive patient populations. Our knowledge of ALK function under normal conditions is more limited, but a number of studies in model organisms and cell models have increased our understanding signi fi cantly. Here we discuss the present state of knowledge regarding ALK biology, ranging from the model organisms C.elegans and Drosophila melanogaster , to human disease together with their potential implications.","PeriodicalId":404310,"journal":{"name":"Aacr Education Book","volume":"2015 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130274853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Intravital imaging of mice expressing Forster resonance energy transfer (FRET) biosensors","authors":"M. Matsuda","doi":"10.1158/AACR.EDB-15-8642","DOIUrl":"https://doi.org/10.1158/AACR.EDB-15-8642","url":null,"abstract":"In the past half century, there has been tremendous progress in the understanding of oncogene (or growth factor) signal transduction cascades. Growth factors activate receptor tyrosine kinase, which turns on Ras and triggers activation of the serine threonine kinase cascades consisting of Raf, MEK, and ERK (1). This signal transduction cascade has been extensively characterized by the use of biochemical techniques in cancer cell lines, generally under the assumption that cancer cells are a homogenous population. We now know cancer cells are heterogeneous and change their properties via their interaction with stromal cells. Therefore, we need techniques to examine the activity of signaling molecules at the single cell resolution in vivo . One such technique is using genetically encoded biosensors based on the principle of F € orster resonance energy transfer (FRET) to monitor the activity changes of signaling molecules in living cells (2, 3). Despite the increasing ubiquity of these biosensors, their application has mostly been limited to cultured cells that transiently express the FRET biosensor constructs, due to particular dif fi culties in the development of cell lines and transgenic mice with FRET biosensors. In previous studies on the generation of transgenic mice expressing FRET biosensors, the analysis has usually been conducted in vitro with cells isolated from the tissues of transgenic mice (4 – 8), and only a few studies have successfully pursued FRET imaging in living tissues (7, 8), probably due to the low levels of expression.","PeriodicalId":404310,"journal":{"name":"Aacr Education Book","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124797691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"High-density arrays to profile circulating biomarkers","authors":"P. Lampe","doi":"10.1158/AACR.EDB-15-8477","DOIUrl":"https://doi.org/10.1158/AACR.EDB-15-8477","url":null,"abstract":"Background This presentation focuses on the utility, advantages, and disadvantages of using different protein microarray technologies to examine the proteomics, glycomics, and autoantibody content of plasma, sera, and tumor tissue samples. In general, array technologies use small amounts of biospecimen and offer the advantage of probing large numbers of analytes in a single sample under the same conditions for washing and processing steps. Depending on the format, they can be part of an automated work fl ow that quickly yields a large amount of data that can be amenable to pathway analysis. Different surfaces can be used to imprint arrays including glass slides (usually with a surface treated to tightly bind the analyte), membranes (e.g., nitrocellulose or PVDF) or patterned microtiter plates. Most of the technology and current basic protocols for producing these arrays have been adapted from early nuclei acid expression arrays (1). Although the more cutting-edge technologies are produced by individual laboratories, several manufac-turers now produce a variety of protein arrays. The discussion here will focus on four types of arrays: protein arrays, peptide arrays, reverse phase arrays, and antibody arrays.","PeriodicalId":404310,"journal":{"name":"Aacr Education Book","volume":"53 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133829952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Risk prediction models in lung cancer: The methodology for identifying high risk individuals for future lung cancer computed tomography (CT) screening programs","authors":"J. Field, M. Marcus","doi":"10.1158/AACR.EDB-15-8767","DOIUrl":"https://doi.org/10.1158/AACR.EDB-15-8767","url":null,"abstract":"The results of the USNational Lung Screening Trial (NLST) were published in 2011 and are considered a landmark event in lung cancer research (1). This randomized study of 53,454 individuals showed that computed tomography (CT) scans are able to reduce lung cancer mortality by 20 percent through early detection, although with important cost and morbidity due to overdiagnosis and treatment of benign nodules. (2) Several European lung cancer screening trials have also been initiated, with the largest being the NELSON trial in the Netherlands (3) and the plan is to pool data from a number of European trials (4). Clearly, screening tools that are able to identify lung cancers at an early stage have much potential to reduce the enormous burden on lung cancer mortality (5). There are now discussions on how implementation may be put in place across the world, within differing health care systems (6). The success of lung cancer screening will be dependent upon identifying populations at sufficient risk in order to maximize the benefit-to-harm ratio of the intervention. The recommendation from the US Preventive Task Forces is based on the US NLST trial, includes screening all individuals between the ages of 55 and 80 with a smoking history of 30 pack-years or more (one pack-year is 20 cigarettes/day for one year or 10 cigarettes/day for two years, etc.) (7). An in-depth analysis of the NLST showed that there were significant differences in the number of lung cancer cases detected based on underlying risk, even though all participants had satisfied the criteria for participation in the study and were considered at high risk: 60 percent of participants at highest risk for lung-cancer death (quintiles 3 through 5) accounted for 88 percent of the prevented deaths, whereas the 20 percent of participants at lowest risk (quintile 1) accounted for only 1 percent of prevented lung-cancer deaths (8).","PeriodicalId":404310,"journal":{"name":"Aacr Education Book","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133183197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Therapeutic targeting and monitoring tumor immunity in melanoma","authors":"J. Austin-Breneman, H. Jiang, Z. Cooper, J. Wargo","doi":"10.1158/AACR.EDB-15-8781","DOIUrl":"https://doi.org/10.1158/AACR.EDB-15-8781","url":null,"abstract":"There have been signi fi cant advances in melanoma therapy over the past several years, with several molecularly targeted and immunotherapeutic agents recently FDA-approved for use the treatment of patients with metastatic disease. Notable among these are inhibitors of the BRAF/MAPK pathway (targeted therapy), and antibodies that block immunomodulatory molecules on the surface of T cells and tumors (immune checkpoint inhibitors). However, with these advances, we are posed with therapeutic dilemmas with regard to timing and sequence of therapy. Namely, there is signi fi cant debate as to whether to begin treatment with targeted therapy versus immunotherapy upfront, and at which point to change treatment strategy. This is highly relevant, as each of these treatments as mono-therapy have signi fi cant limitations. focused fi effort on better understanding response and resistance to therapy through longitudinal tissue and blood analyses in patients on targeted therapy and to better understand molecular and immune mechanisms have critical insights which have led to therapeutic for patients with melanoma 2). This includes the use of combination strategies, such as adding immune checkpoint blockade to a backbone molecularly targeted with melanoma these and response data are not yet that complexities exist with regard to these combinations. A of and resistance to combination strategies through translational research is critical, is best performed on longitudinal patient samples during the course which may (and be informed by) approaches combining molecularly targeted and will be built on a deep understanding of the molecular and immune effects of each these therapies in isolation, well","PeriodicalId":404310,"journal":{"name":"Aacr Education Book","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130248547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cell line authentication to improve preclinical cancer research: Methods in cell line authentication, quality control, and annotation","authors":"S. Ethier, R. Neve","doi":"10.1158/AACR.EDB-15-9041","DOIUrl":"https://doi.org/10.1158/AACR.EDB-15-9041","url":null,"abstract":"Cell lines are essential tools used in all aspects of basic and applied biomedical research. Unfortunately, a large number of cell lines are contaminated or mislabeled resulting in farreaching consequences. In addition to damaged reputations and misleading data, a significant sum of research funds are wasted and, more importantly, delivery of essential therapeutics to patients is delayed (1–3). Despite the knowledge that use of contaminated cell lines is widespread, only a minority of scientists perform adequate quality controls on cell lines (4), and there has been an astounding lack of impetus to provide meaningful solutions to this problem. As awareness grows, practices improve, but it will require a concerted, coordinated effort from research institutions, funding agencies, and journals to insist upon cell line authentication as standard scientific practice (2). Such a fundamental change needs to come through a balance of regulation and education. Remarkably, there are simple, inexpensive solutions that can be easily implemented in any research laboratory for quality control of cell line stocks (5). In this session, we will highlight the major sources of cell line contamination and misidentification, and outline potential solutions. Discussion topics cover problems associated with cell line annotation, contamination by adventitious organisms, intraand inter-species cell line contamination, and the pros and cons of two technologies to DNA profile biosamples.","PeriodicalId":404310,"journal":{"name":"Aacr Education Book","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128964247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}